306753-71-9Relevant academic research and scientific papers
Dual-stimuli-responsive probes for detection of ovarian cancer cells and quantification of both pH and enzyme activity
Harada, Hiroshi,Huo, Wenting,Miki, Koji,Mu, Huiying,Oe, Masahiro,Ohe, Kouichi,Tokunaga, Daisuke
supporting information, p. 2068 - 2075 (2021/09/16)
Many physiological processes involve multiple coordinated chemical and/or biological events. Therefore, it is considered urgent to develop dual-responsive probes for a more comprehensive understanding of the synergistic effects between multiple analytes in complex cellular environments. In this study, we developed a dual-responsive probe βgal-BP-PMB (β-galactosyl3,3′- dihydroxy-2,2′-bipyridylp- methoxybenzyl), the photoluminescence of which can be activated by β- galactosidase (β-gal) and acidic conditions. The overexpression of β-gal is an important feature of senescent and ovarian cancer cells. Single-input activatable probes for detecting β-gal activity in ovarian cancer cells can induce a false positive response from senescent cells. Because the lysosomal pH in senescent cells is increased, probe βgal-BP-PMB can be specifically activated in ovarian cancer cells, but silenced in senescent cells. Probe βgal-BP-PMB has a small molecular size, high sensitivity towards targeted stimuli and unique ratiometric properties, thereby enabling the quantification of both pH and enzyme activity. Such dual-responsive probes could earn a unique place in the field of bioimaging, where multiple analytes should be accurately and simultaneously monitored.
CHEMICAL COMPOUNDS-821
-
Page/Page column 65, (2009/03/07)
The invention relates to chemical compounds of the formula (I), or pharmaceutically acceptable salts thereof, which possess ALK5 (TGFβR1) inhibitory activity and are accordingly useful for their anti-cancer activity and thus in methods of treatment of the
COMPOUND HAVING TGF-BETA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
-
Page/Page column 97-98, (2010/11/24)
The present invention provides compounds of formula (I) or compounds of formula (II) and pharmaceutically acceptable salts or solvates thereof. An objective of the present invention is to provide compounds having TGF2 inhibitory activity.
